Zhitong Financial APP learned that Deutsche Bank released a research report saying it first gave CSPC Pharmaceutical a "buy" rating of 01093, with a target price of HK $11.80. As a leading pharmaceutical company in China, it focuses on developing, manufacturing and selling innovative drugs, generics and APIs. Most of the company's existing flagship products, such as NBP, Xuanning and Domesu, accounted for more than 50% of total revenue last year and are drugs that have been launched for more than a decade.

The bank expects that new products may become new catalysts for the company's share price, such as DUOENDA, irinotecan liposome injection (Irinotecan liposome) and mRNA vaccine may make up for the shortcomings of old products. It is also believed that with the potential release and smooth listing of new products, it is believed that the market will revalue the company.